FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/02/2022
Back to search
Official data from USPTO
DEEPZEMA AI-AUGMENTED DRUG DISCOVERY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
10/02/2022
Trademark type
Combined
Nice classes
42
Filing date
02/23/2021
Registration date
05/24/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/24/2022
Last transaction
05/24/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
KR
Examiner
SEVERSON, JUSTIN
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the term "DEEPZEMA" in red font above the wording "AI-AUGMENTED DRUG DISCOVERY" in black font. The color white represents background, shading and/or transparent areas and is not claimed as a feature of the mark.
Holders and representatives
Holders
Innovo Therapeutics Inc.
Representatives
Cynthia A. Moyer Fredrikson & Byron, P.A.
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Medicine research; research of pharmaceuticals; drug discovery services; research of crude medicines; research of medicines; research service of pharmaceuticals; development of pharmaceuticals and drugs; clinical trial; conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy in the field of testinginspectionresearch of medical products; conducting early evaluations in the field of new pharmaceuticals; development of biotechnology
Publications
History of USPTO decisions and trademark events.
25 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/10/2022
FIMP
FINAL DISPOSITION PROCESSED
09/09/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/24/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/24/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
05/24/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/22/2022
PUBO
PUBLISHED FOR OPPOSITION
02/22/2022
GPNX
NOTIFICATION PROCESSED BY IB
02/20/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/02/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/02/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/02/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/18/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/13/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/12/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/12/2022
RFNT
REFUSAL PROCESSED BY IB
11/15/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/24/2021
RFRR
REFUSAL PROCESSED BY MPU
10/15/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/28/2021
CNRT
NON-FINAL ACTION WRITTEN
09/27/2021
DOCK
ASSIGNED TO EXAMINER
09/17/2021
MAFR
APPLICATION FILING RECEIPT MAILED
04/20/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/16/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/15/2021
Continuous trademark protection
Get notified about every new filing that threatens DEEPZEMA AI-AUGMENTED DRUG DISCOVERY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.